Table 2

Clinical and biochemical features relating to outcome in 35 of 66 patients with thyrotoxicosis, diagnosed in the west of Scotland between 1989 and 2012 who stopped antithyroid drug (ATD) treatment for possible remission prior to treatment with either surgery or radioiodine therapy

Remission after stopping ATDRelapse after stopping ATDP value
Number (F:M)20 (18F:2M)15 (13F:2M)
Age at diagnosis, median (range)12.2 (3.7–15.6)
9.3 (4.3–15.8)
Graves’s disease: Hashimoto’s thyroiditis10:1012:30.06
Goitre at diagnosisNone (n=5)
Small (n=7)
Moderate (n=3)
Large (n=1)
Not specified (n=4)
Small (n=8)
Moderate (n=4)
Not specified (n=3)
Type of initial ATD treatment
  • DT

  • BR

DT: 13
DT: 9
BR: 6
Median (range) fT4 (pmol/L) at diagnosis (n=34)44.0 (4.8–105.0)
44.7 (27.8–124.1)
Median (range) TT4 (nmol/L) at diagnosis (n=34)293
236 (19–733)
Mean/median (range) TRAB (U/L) at diagnosis (n=25)15/4 [<3–59)
22, 16 [<3–67)
  • Where the data for a given row are fewer than the total patient number (35), the available number is given as (n=) in the left-hand column.

  • BR, block and replace; DT, dose titration; fT4, free thyroxine; TRAB, TSH receptor antibody; TT4, total T4.